In short
This article examines clinical trials investigating the use of pneumococcal polysaccharide serotype 3 conjugate vaccine adsorbed on aluminum phosphate. These trials aim to evaluate the safety, efficacy, and immune responses of this vaccine in various populations, including healthy adults, infants, and those at increased risk of pneumococcal disease. The studies explore different formulations, dosing schedules, and combinations with other vaccines to optimize protection against pneumococcal infections.
At a glance
- Populations Studied
- Healthy adults, infants, toddlers, adults ≥65 years, individuals at increased risk of pneumococcal disease
- Key Objectives
- Evaluate safety, immunogenicity, efficacy, and effectiveness of pneumococcal vaccines
- Primary Endpoints
- Immune responses (antibody levels), adverse events, vaccine effectiveness against pneumococcal disease
- Secondary Endpoints
- Comparison to other pneumococcal vaccines, long-term protection, specific serotype responses
- Administration
- Intramuscular injection, various dosing schedules
- Combination Studies
- Co-administration with RSV vaccines, comparison of different pneumococcal serotype combinations
- Special Considerations
- Evaluation in high-risk groups, assessment of long-term safety and efficacy
What is this vaccine?
This vaccine is a component of larger pneumococcal vaccines, specifically designed to protect against pneumococcal serotype 3. It is part of vaccines like Apexxnar and Prevenar 13, which are pneumococcal conjugate vaccines. These vaccines contain multiple pneumococcal serotypes to provide broad protection against pneumococcal diseases.
The full name - "Pneumococcal Polysaccharide Serotype 3 Conjugated to CRM197 Adsorbed on Aluminium Phosphate" - describes its key components:
- Pneumococcal Polysaccharide Serotype 3: This is the specific part of the pneumococcus bacteria that the vaccine targets.
- Conjugated to CRM197: CRM197 is a carrier protein that helps boost the immune response.
- Adsorbed on Aluminium Phosphate: This is an adjuvant that further enhances the immune response.
How does it work?
This vaccine works by stimulating the body's immune system to produce antibodies against pneumococcal serotype 3. When the vaccine is injected, the immune system recognizes the pneumococcal polysaccharide as foreign and produces antibodies against it. The CRM197 protein and aluminium phosphate help to enhance this immune response.
If a person later encounters the real pneumococcal serotype 3 bacteria, their immune system is primed to recognize and fight off the infection more effectively.
What diseases does it prevent?
As part of broader pneumococcal vaccines, this component helps prevent diseases caused by Streptococcus pneumoniae serotype 3, including:
- Pneumonia: An infection of the lungs
- Bacteremia: A blood infection
- Meningitis: An infection of the lining of the brain and spinal cord
- Otitis media: Middle ear infections (particularly in children)
These diseases can be serious, especially in young children, older adults, and people with weakened immune systems.
How is it administered?
This vaccine is administered as an intramuscular injection, typically in the upper arm for adults or the thigh for infants. It is given as part of a larger pneumococcal vaccine (like Apexxnar or Prevenar 13) that includes multiple serotypes.
The dosing schedule can vary depending on age and risk factors. For example:
- Infants may receive a series of doses at 2, 4, 6, and 12-15 months of age
- Adults 65 years and older may receive a single dose
- People with certain medical conditions may have different schedules
How effective is it?
Studies have shown that pneumococcal conjugate vaccines containing this serotype 3 component are effective in preventing invasive pneumococcal disease. However, the effectiveness can vary depending on the specific vaccine, age group, and type of pneumococcal disease.
For example, one study found that the 20-valent pneumococcal conjugate vaccine (which includes serotype 3) was effective against vaccine-type community-acquired pneumonia in adults aged 65 and older.
Is it safe?
Pneumococcal conjugate vaccines containing this component have been shown to have a good safety profile. Common side effects may include:
- Pain, redness, or swelling at the injection site
- Fever
- Fatigue
- Decreased appetite
- Irritability (in children)
Serious side effects are rare. As with any vaccine, there is a very small risk of severe allergic reaction.
Who should get this vaccine?
This vaccine, as part of larger pneumococcal vaccines, is generally recommended for:
- Infants and young children
- Adults 65 years and older
- People with certain medical conditions that increase their risk of pneumococcal disease
However, specific recommendations can vary by country and individual circumstances. It's important to consult with a healthcare provider to determine if and when you should receive a pneumococcal vaccine.
Ongoing research
Research on pneumococcal vaccines is ongoing to improve their effectiveness and expand their coverage. Some current areas of study include:
- Evaluating the long-term effectiveness of newer pneumococcal vaccines in different populations
- Studying the immune response to pneumococcal vaccines in various age groups
- Investigating the potential of combining pneumococcal vaccines with other vaccines, such as those for respiratory syncytial virus (RSV)
These ongoing studies aim to further improve our ability to prevent pneumococcal diseases and protect vulnerable populations.